ライフサイエンスコーパス: pancreaticoduodenectomy

1 resection (EA or SA) and en bloc resection (pancreaticoduodenectomy).

2 nd poorly known long-term complication after pancreaticoduodenectomy.

3 mptive completion pancreatectomy through the pancreaticoduodenectomy.

4 had N1 disease; 138 patients (78%) underwent pancreaticoduodenectomy.

5 everal reports of collected experiences with pancreaticoduodenectomy.

6 ome increased morbidity compared to standard pancreaticoduodenectomy.

7 neal lymphadenectomy to a pylorus-preserving pancreaticoduodenectomy.

8 cations and death associated with subsequent pancreaticoduodenectomy.

9 rioperative morbidity and mortality rates of pancreaticoduodenectomy.

10 isk for postoperative wound infections after pancreaticoduodenectomy.

11 factor of gastric stump carcinoma following pancreaticoduodenectomy.

12 reas not associated with an IPMN resected by pancreaticoduodenectomy.

13 ed in 300 consecutive patients who underwent pancreaticoduodenectomy.

14 creatic fistula or total complications after pancreaticoduodenectomy.

15 e-institution experience assessing QOL after pancreaticoduodenectomy.

16 a few small studies have evaluated QOL after pancreaticoduodenectomy.

17 y and mortality rates in patients undergoing pancreaticoduodenectomy.

18 ard pancreaticoduodenectomy and 58 a radical pancreaticoduodenectomy.

19 inage on morbidity and mortality rates after pancreaticoduodenectomy.

20 management may improve patient outcome after pancreaticoduodenectomy.

21 similar morbidity and mortality to standard pancreaticoduodenectomy.

22 e been observed at high-volume centers after pancreaticoduodenectomy.

23 preoperative multidetector CT and subsequent pancreaticoduodenectomy.

24 chemoradiation given either before or after pancreaticoduodenectomy.

25 oradiation because of delayed recovery after pancreaticoduodenectomy.

26 r to complete tumor resection at the time of pancreaticoduodenectomy.

27 short-term outcomes to those following open pancreaticoduodenectomy.

28 ally lethal postoperative complication after pancreaticoduodenectomy.

29 and after open transhiatal esophagectomy or pancreaticoduodenectomy.

30 total hip replacement (THR), colectomy, and pancreaticoduodenectomy.

31 ilar results were obtained for colectomy and pancreaticoduodenectomy.

32 ated with a high risk of complications after pancreaticoduodenectomy.

33 eatic adenocarcinoma, 202 patients underwent pancreaticoduodenectomy.

34 pularized by Whipple in 1935, who reported 3 pancreaticoduodenectomies.

35 ee options for postoperative treatment after pancreaticoduodenectomy: 1) standard therapy: external b

36 consistent among 220 patients who underwent pancreaticoduodenectomy (10% vs. 21%; relative risk, 0.4

37 Five patients required pancreaticoduodenectomy, 11 patients underwent non-Whipp

38 as 56.6%, 19.9%, and 23.3%, respectively.For pancreaticoduodenectomies (12,670 patients; mortality 9.

39 robotic pancreatic resections were analyzed; pancreaticoduodenectomy (132), distal pancreatectomy (83

40 eventy-two percent of the patients underwent pancreaticoduodenectomies, 15% underwent total pancreate

41 pancreatectomy (40%), enucleation (34%), and pancreaticoduodenectomy (16%) were the most common proce

42 re was required in 16 patients (6%) (11 with pancreaticoduodenectomy, 2 with distal pancreatectomy, 2

43 olved the gland, with 70% being resected via pancreaticoduodenectomy, 22% via total pancreatectomy, a

44 Fifty-nine patients underwent pancreaticoduodenectomy, 36 without venous resection and

45 g colonic surgery and 10 patients undergoing pancreaticoduodenectomy, 6 cm colon or jejunum was isola

46 oportion of total pancreatectomy (74.7%) and pancreaticoduodenectomy (78.3%) patients had N1 disease

47 d with higher 30-day mortality compared with pancreaticoduodenectomy (8.0% vs. 1.5%, respectively; P

48 A total of 7061 patients underwent pancreaticoduodenectomy: 983 had MIPD and 6078 had open

49 re were no differences between MIPD and open pancreaticoduodenectomy after multivariable adjustment i

50 ancreatectomy, 4 total pancreatectomy, and 4 pancreaticoduodenectomy); all had dysplastic intraductal

51 ommon procedures was 529 +/- 103 minutes for pancreaticoduodenectomy and 257 +/- 93 minutes for dista

52 patients randomized, 56 underwent a standard pancreaticoduodenectomy and 58 a radical pancreaticoduod

53 Pancreaticoduodenectomy and distal pancreatectomy are as

54 ophylactic octreotide in patients undergoing pancreaticoduodenectomy and found no benefit to the use

55 nce occurred in 21% of patients who received pancreaticoduodenectomy and postoperative chemoradiation

56 ory surgery with the purpose of performing a pancreaticoduodenectomy and were found to have unresecta

57 ocedure, 2 patients had a pylorus-preserving pancreaticoduodenectomy, and 1 patient had a distal panc

58 (>/=65 years of age) undergoing gastrectomy, pancreaticoduodenectomy, and colectomy at a 2000-bed urb

59 perative rapid-fractionation chemoradiation, pancreaticoduodenectomy, and EB-IORT is associated with

60 alternative to high-risk anastomosis during pancreaticoduodenectomy; and distal pancreatectomy for b

61 The forbidding mortality of pancreaticoduodenectomy, approximately 20% just a genera

62 exploratory surgery with intent to perform a pancreaticoduodenectomy are found to have unresectable d

63 tage disease; rates of 5-year survival after pancreaticoduodenectomy are low.

64 Operative mortality rates for pancreaticoduodenectomy are now <5% at major centers, an

65 tinue to accumulate about pylorus preserving pancreaticoduodenectomy as an alternative to the standar

66 database of patients who underwent elective pancreaticoduodenectomy at an academic tertiary care cen

67 ection specimens from patients who underwent pancreaticoduodenectomy at Johns Hopkins Hospital (Balti

68 Among 1,648 patients undergoing pancreaticoduodenectomy at the authors' institution from

69 Of 5025 patients who underwent pancreaticoduodenectomy at the Johns Hopkins Hospital an

70 d to select records of patients undergoing a pancreaticoduodenectomy between 1984 and 1995.

71 ution, high-volume experience indicates that pancreaticoduodenectomy can be performed safely for a va

72 Pancreaticoduodenectomy can be performed with a similar

73 Radical (extended) pancreaticoduodenectomy can be performed with similar mo

74 There is a general impression that pancreaticoduodenectomy can severely impair QOL and alte

75 etroperitoneal lymphadenectomy to a standard pancreaticoduodenectomy) can be performed with similar m

76 aim of this study was to study whether post-pancreaticoduodenectomy complications (PPDC) in high-ris

77 These results demonstrate that, as with pancreaticoduodenectomy, distal pancreatectomy can be pe

78 Pancreatic resections, including pancreaticoduodenectomy, distal pancreatectomy, and tota

79 who received preoperative chemoradiation and pancreaticoduodenectomy experienced a local recurrence;

80 s is increased in patients undergoing staged pancreaticoduodenectomy followed by liver-directed thera

81 A total of 405 patients underwent pancreaticoduodenectomy for adenocarcinoma of the head o

82 herapy significantly improves survival after pancreaticoduodenectomy for adenocarcinoma of the head,

83 ears to be indicated for patients treated by pancreaticoduodenectomy for adenocarcinoma of the head,

84 radiation therapy has been recommended after pancreaticoduodenectomy for adenocarcinoma of the head,

85 patients who underwent potentially curative pancreaticoduodenectomy for adenocarcinoma of the pancre

86 Data on all patients undergoing pancreaticoduodenectomy for adenocarcinoma of the pancre

87 ure due to prolonged survival observed after pancreaticoduodenectomy for benign and premalignant lesi

88 formed of 72 consecutive patients undergoing pancreaticoduodenectomy for chronic pancreatitis between

89 ter study of preoperative chemoradiation and pancreaticoduodenectomy for localized pancreatic adenoca

90 Patients undergoing pancreaticoduodenectomy for LPSP have durable relief of

91 The routine use of octreotide after pancreaticoduodenectomy for malignancy cannot be recomme

92 ver, in the subset of patients who underwent pancreaticoduodenectomy for malignancy, either no analys

93 cidence of pancreatic anastomotic leak after pancreaticoduodenectomy for malignancy.

94 erative day 5) or no further treatment after pancreaticoduodenectomy for malignancy.

95 astric stump carcinoma 19 and 10 years after pancreaticoduodenectomy for malignant ampulloma and tota

96 nsecutive group of 45 patients who underwent pancreaticoduodenectomy for PA from July 2001 to Decembe

97 Since 1995, patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma ha

98 ned to evaluate prospectively survival after pancreaticoduodenectomy for pancreatic adenocarcinoma, c

99 odenectomy for malignant ampulloma and total pancreaticoduodenectomy for pancreatic adenocarcinoma, r

100 utcome of 64 consecutive patients undergoing pancreaticoduodenectomy for pancreatic carcinoma with gr

101 T) have reduced postoperative survival after pancreaticoduodenectomy for pancreatic ductal adenocarci

102 For patients who undergo pancreaticoduodenectomy for pancreatic ductal adenocarci

103 ce is often considered a contraindication to pancreaticoduodenectomy for patients with malignant tumo

104 improved long-term survival associated with pancreaticoduodenectomy for patients with pancreatic car

105 es have significantly reduced survival after pancreaticoduodenectomy for PDAC.

106 p of patients treated 5 or more years ago by pancreaticoduodenectomy for periampullary adenocarcinoma

107 PV confluence may be performed safely during pancreaticoduodenectomy for periampullary malignant tumo

108 s of retroperitoneal margin positivity after pancreaticoduodenectomy for tumors of the pancreatic hea

109 ne institution increased its yearly share of pancreaticoduodenectomies from 20.7% to 58.5%, and the s

110 Patients who underwent reoperative pancreaticoduodenectomy had an increased incidence of pa

111 Fifty-eight percent of patients undergoing pancreaticoduodenectomy had an uncomplicated postoperati

112 Hospitals with more years of experience with pancreaticoduodenectomy had lower rates of inpatient mor

113 Pancreaticoduodenectomy has become a commonly performed

114 Pancreaticoduodenectomy has been used increasingly in re

115 The drive to reduce LOS after pancreaticoduodenectomy has minimal effect on overall ch

116 strate that as a group, patients who survive pancreaticoduodenectomy have near-normal QOL scores.

117 al Quality Improvement Program who underwent pancreaticoduodenectomy, hepatectomy, and colectomy at a

118 he volume and type of fluid administered for pancreaticoduodenectomy impacts postoperative outcomes.

119 modality therapy and avoids the toxicity of pancreaticoduodenectomy in patients found to have metast

120 The authors define the role of palliative pancreaticoduodenectomy in patients with pancreatic carc

121 These data support the role of palliative pancreaticoduodenectomy in patients with pancreatic carc

122 consecutive group of 650 patients undergoing pancreaticoduodenectomy in the 1990s.

123 he reported advantages of minimally invasive pancreaticoduodenectomy include better visualization, fa

124 ndergoing standard versus radical (extended) pancreaticoduodenectomy (including distal gastrectomy an

125 e technical challenges of minimally invasive pancreaticoduodenectomy, including robotic techniques.

126 Pancreaticoduodenectomy is accompanied by a considerable

127 impact of residual microscopic disease after pancreaticoduodenectomy is currently a point of controve

128 Pancreaticoduodenectomy is gaining acceptance and is bei

129 Survival after pancreaticoduodenectomy is not improved by extending pan

130 tive trial of regional pancreatectomy versus pancreaticoduodenectomy is warranted in previously untre

131 erest in expanding use of minimally invasive pancreaticoduodenectomy (MIPD).

132 ctomy (n = 8), hepatic resection (n = 4), or pancreaticoduodenectomy (n = 1) underwent MR cholangiogr

133 underwent total pancreatectomy (n = 100) or pancreaticoduodenectomy (n = 1286) for adenocarcinoma we

134 by site in the reoperative group undergoing pancreaticoduodenectomy (n = 52) was 60%, 19%, 15%, and

135 ive drainage still has a role during Whipple pancreaticoduodenectomy on the basis of the results of a

136 patients is free of disease 16 months after pancreaticoduodenectomy, one is alive and free of tumor

137 have several potential advantages over open pancreaticoduodenectomy (OPD), including lower blood los

138 operative pasireotide in patients undergoing pancreaticoduodenectomy or distal pancreatectomy [POPF:

139 us pasireotide in patients undergoing either pancreaticoduodenectomy or distal pancreatectomy.

140 hrough a formal pancreatic resection such as pancreaticoduodenectomy or distal pancreatectomy.

141 trend in Maryland toward regionalization of pancreaticoduodenectomy over a 12-year period and its ef

142 A trend toward regionalization of pancreaticoduodenectomy over a 12-year period in Marylan

143 mproved significantly in patients undergoing pancreaticoduodenectomy (p < 0.02).

144 ng total pancreatectomy (69.0% vs. 38.6% for pancreaticoduodenectomy; P < 0.0001), most complications

145 ycerol were analysed from small intestine of pancreaticoduodenectomy patients before and after occlud

146 Total pancreatectomy and pancreaticoduodenectomy patients had comparable 5-year s

147 Overall QOL scores for the 192 responding pancreaticoduodenectomy patients in the three domains (p

148 The pancreaticoduodenectomy patients were subgrouped into ch

149 We reviewed 1944 consecutive pancreaticoduodenectomies (PD) over an 8-year period (Ap

150 different surgical techniques, standard (ST) pancreaticoduodenectomy (PD) and no-touch isolation (NT)

151 Wound infections after pancreaticoduodenectomy (PD) are common.

152 Pancreaticoduodenectomy (PD) can be associated with sign

153 cidence of biliary stricture formation after pancreaticoduodenectomy (PD) for benign and malignant pe

154 During pancreaticoduodenectomy (PD) for ductal adenocarcinoma,

155 ociated with OS among patients who underwent pancreaticoduodenectomy (PD) for pancreatic cancer.

156 This study compares outcomes following pancreaticoduodenectomy (PD) for patients treated at loc

157 addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/I

158 erative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic a

159 mortality, and length of hospital stay after pancreaticoduodenectomy (PD) have significantly decrease

160 heme in a large cohort of patients following pancreaticoduodenectomy (PD) in a pancreaticobiliary sur

161 in jaundiced patients who are candidates for pancreaticoduodenectomy (PD) or major hepatectomy due to

162 Patients eligible for pancreaticoduodenectomy (PD) or pylorus-preserving PD (P

163 use of preoperative biliary drainage before pancreaticoduodenectomy (PD) remains controversial.

164 ting, and Participants: Hospitals performing pancreaticoduodenectomy (PD) were queried from the Unive

165 Although pancreaticoduodenectomy (PD) with en-bloc portal vein/su

166 D-IPMN, including the following: (1) initial pancreaticoduodenectomy (PD), (2) yearly noninvasive rad

167 PF is a major complication following pancreaticoduodenectomy (PD), associated with significan

168 with total parenteral nutrition (TPN), after pancreaticoduodenectomy (PD), in terms of postoperative

169 ist comparing robotic and open approaches to pancreaticoduodenectomy (PD).

170 is the major contributor to morbidity after pancreaticoduodenectomy (PD).

171 a large cohort of patients >/=5-years after pancreaticoduodenectomy (PD).

172 2015, we randomized 330 patients undergoing pancreaticoduodenectomy (PD, n = 218), central (n = 16),

173 lity 9.2%), there were 2 cut-offs (16 and 40 pancreaticoduodenectomies per year), and both were indep

174 lesions were identified in pancreata from 33 pancreaticoduodenectomies performed for infiltrating ade

175 rate lower morbidity and mortality rates for pancreaticoduodenectomy performed at high-volume centers

176 Two hundred forty consecutive cases of pancreaticoduodenectomy performed between January 1994 a

177 directed therapy (14.5%) versus simultaneous pancreaticoduodenectomy plus liver-directed therapy (7.0

178 Pancreaticoduodenectomy plus liver-directed therapy is a

179 Prolonged recovery after pancreaticoduodenectomy prevents the delivery of postope

180 = .049) were predictive of relapse, whereas pancreaticoduodenectomy reduced the relapse rate (vs the

181 had lower rates of inpatient mortality after pancreaticoduodenectomy relative to very-low-volume faci

182 atients were randomized to either a standard pancreaticoduodenectomy (removing only the peripancreati

183 were randomized to receive either a standard pancreaticoduodenectomy (removing only the peripancreati

184 r complex pancreatic resections, such as the pancreaticoduodenectomy, requires close monitoring of ou

185 (90.7% vs. 91.8%) (total pancreatectomy vs. pancreaticoduodenectomy, respectively, both P > 0.05).

186 (22.2% vs. 43.7%) (total pancreatectomy vs. pancreaticoduodenectomy, respectively, both P < 0.0001).

187 e patient in the radical group with negative pancreaticoduodenectomy specimen lymph nodes had a micro

188 feasibility of performing spleen-preserving pancreaticoduodenectomy (SPPD).

189 c with the specimen) or a radical (extended) pancreaticoduodenectomy (standard resection plus distal

190 odes en bloc with the specimen) or a radical pancreaticoduodenectomy (standard resection plus distal

191 cal resection procedures such as the radical pancreaticoduodenectomy, subtotal and partial hepatectom

192 me-outcome relation for hospitals performing pancreaticoduodenectomy (the Whipple procedure).

193 xploration underwent successful resection by pancreaticoduodenectomy; the remaining 26 patients (34%)

194 with periampullary adenocarcinoma treated by pancreaticoduodenectomy, those with duodenal adenocarcin

195 Eight weeks after pancreaticoduodenectomy, three patients received 1 x 10(

196 Total laparoscopic pancreaticoduodenectomy (TLPD) has been demonstrated to

197 er, most surgeons remain hesitant to perform pancreaticoduodenectomy unless surgical margins are wide

198 re used to examine whether hospital share of pancreaticoduodenectomies was a significant predictor of

199 length of postoperative hospital stay after pancreaticoduodenectomy was 18.4 days, which was signifi

200 e overall postoperative morbidity rate after pancreaticoduodenectomy was 48% (114/240).

201 First, pancreaticoduodenectomy was challenging in the infant do

202 rvival following total pancreatectomy versus pancreaticoduodenectomy was equivalent.

203 A pancreaticoduodenectomy was performed in 139 patients an

204 Pancreaticoduodenectomy was performed in 174 patients, w

205 Pancreaticoduodenectomy was performed in 71% of patients

206 ish literature in which a minimally invasive pancreaticoduodenectomy was performed.

207 en March 1969 and May 2003, 1000 consecutive pancreaticoduodenectomies were performed by a single sur

208 A total of 795 pancreaticoduodenectomies were performed in Maryland at

209 During this period, 190 consecutive pancreaticoduodenectomies were performed without a morta

210 2011 and November 2013, patients undergoing pancreaticoduodenectomy were enrolled in an institutiona

211 Adult patients undergoing pancreaticoduodenectomy were identified from the Nationa

212 Common problems after pancreaticoduodenectomy were weight loss, abdominal pain

213 ieved in centers performing large numbers of pancreaticoduodenectomies, which suggests that regionali

214 nd (EUS), surgery in ZES patients with MEN1, pancreaticoduodenectomy (Whipple procedure), lymph node

215 distal pancreatectomy, and the remaining had pancreaticoduodenectomy (Whipple resection).

216 tionnaire was sent to 323 patients surviving pancreaticoduodenectomy who had undergone surgery at The

217 as determined in 15 patients who underwent a pancreaticoduodenectomy with a combination of laser Dopp

218 rily require immediate laparotomy to undergo pancreaticoduodenectomy with acceptable morbidity and mo

219 nd patients with localized disease underwent pancreaticoduodenectomy with EB-IORT 10 to 15 Gy.

220 aken to surgery, 20 patients (74%) underwent pancreaticoduodenectomy with EB-IORT.

221 The authors sought to determine whether pancreaticoduodenectomy with en bloc resection of the SM

222 Two hundred eleven patients underwent pancreaticoduodenectomy with pancreatic-enteric anastomo

223 e preoperative biopsy was negative underwent pancreaticoduodenectomy with planned postoperative chemo

224 Pancreaticoduodenectomy with postoperative chemotherapy

225 These data demonstrate that radical pancreaticoduodenectomy (with the addition of a distal g

226 ead resection offer outcomes as effective as pancreaticoduodenectomy, with lowered morbidity and mort

227 Four patients have undergone pancreaticoduodenectomy without perioperative complicati